# Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

> **NCT03117361** · PHASE2 · TERMINATED · sponsor: **PharmaMar** · enrollment: 10 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** plitidepsin
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03117361
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-08
- **Primary completion:** 2018-07-30
- **Final completion:** 2018-07-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** PharmaMar has decided to end this study due to the slow recruitment rate of the trial
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117361, "Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03117361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*